BAP1 Mesothelioma: Gene Alterations and Clinical Implications

BAP1 is the single most frequently altered gene in mesothelioma, with changes found in roughly 45 to 48 percent of both pleural and peritoneal tumors. These alterations can be inherited (germline) or acquired during a person’s lifetime (somatic), and they affect nearly every aspect of the disease, from who develops it and how it is diagnosed to how long patients survive and which treatments show the most promise. What makes BAP1 particularly interesting is the paradox at its center: losing this gene’s function makes a person more vulnerable to developing mesothelioma, yet it also appears to make the resulting cancer behave differently, sometimes less aggressively, than tumors with intact BAP1.

What BAP1 Does in Healthy Cells

BAP1 is an enzyme that removes a small protein tag called ubiquitin from other proteins. This tagging-and-untagging system acts like a molecular switch, turning cellular processes on and off. BAP1 spends most of its time in the cell’s nucleus, where it partners with various chromatin-associated factors to regulate gene activity, DNA copying, and DNA repair.¹ When DNA breaks, cells have a few ways to fix the damage. Recent work shows that BAP1 participates in one of those repair pathways by physically interacting with a key repair complex, supporting the idea that BAP1 loss leaves cells unable to properly mend broken DNA.²

BAP1 also has an important job outside the nucleus. It stabilizes a calcium channel on a structure called the endoplasmic reticulum. When this channel works properly, it helps release calcium into the cell’s mitochondria, which triggers damaged cells to self-destruct through a process called apoptosis. When BAP1 levels drop, calcium flow decreases, and cells that have accumulated DNA damage can survive instead of dying as they should.³ This double hit, impaired DNA repair combined with impaired cell death, helps explain why BAP1 loss is so effective at enabling cancer.

Germline Versus Somatic BAP1 Mutations

There are two fundamentally different ways a mesothelioma patient can end up with BAP1-altered tumors. Somatic mutations arise in the tumor cells themselves during a person’s lifetime, often in the context of prolonged asbestos exposure and the chronic inflammation it causes. These are the more common scenario. A large genomic analysis of mesothelioma found BAP1 alterations at a frequency of about 45 percent across both pleural and peritoneal cases, making it the most or second-most frequently mutated gene depending on the subtype.⁴ An earlier study that combined multiple sequencing methods with protein-level testing found BAP1 alterations in about 64 percent of the sporadic (non-inherited) cases it examined.⁵

Germline mutations, on the other hand, are inherited. A person carrying one defective copy of BAP1 in every cell of their body has what is now recognized as BAP1 tumor predisposition syndrome. This is an autosomal dominant condition, meaning a single inherited copy of the mutation is enough to raise cancer risk. Clinical guidelines estimate that carriers face up to an 85 percent lifetime risk of developing at least one BAP1-associated tumor.⁶ The core cancers linked to this syndrome include mesothelioma (both pleural and peritoneal), uveal melanoma, cutaneous melanoma, renal cell carcinoma, and certain benign skin lesions. Meningioma has also been associated but is not yet considered part of the core group.

The Asbestos Connection and Gene-Environment Interaction

Asbestos exposure is by far the dominant risk factor for mesothelioma in the general population, but inherited BAP1 mutations appear to change the equation. Research on families in asbestos-prone regions, including the striking mesothelioma clusters in Cappadocia, Turkey, was instrumental in uncovering the role of genetic susceptibility in mineral fiber carcinogenesis.⁷ These families showed rates of mesothelioma far exceeding what asbestos exposure alone would predict, eventually leading researchers to identify inherited BAP1 mutations as the amplifying factor.

A study that measured cumulative asbestos exposure in mesothelioma patients found that those carrying germline mutations in BAP1 or other DNA repair genes had significantly lower lifetime asbestos exposure than patients without such mutations.⁸ In other words, it takes less asbestos to trigger mesothelioma in someone whose DNA repair machinery is already compromised. This gene-environment interaction has real implications for screening: people from families with known BAP1 mutations may need monitoring even with modest or uncertain asbestos histories, while general population screening still focuses on heavy occupational exposure.

How BAP1 Loss Helps Pathologists Diagnose Mesothelioma

One of the most immediate clinical uses of BAP1 testing is in diagnosis. Distinguishing mesothelioma from benign reactive mesothelial growths can be surprisingly difficult under a microscope, especially in small biopsies or fluid samples. BAP1 protein loss, detectable with a straightforward immunohistochemistry stain, has become a powerful tool in this setting. When the stain shows absent nuclear BAP1 in mesothelial cells, it is essentially diagnostic of malignancy: one study reported 100 percent specificity, meaning no benign mesothelial proliferation showed BAP1 loss. Sensitivity was lower, around 66 percent for all mesothelioma types, rising to about 69 percent when limited to epithelioid and biphasic subtypes.⁹ That same study found something particularly striking: among patients with benign mesothelial lesions that did show BAP1 loss, all six went on to develop BAP1-negative mesothelioma, suggesting that BAP1 loss in a reactive-appearing proliferation is an early warning sign of malignancy.

BAP1 staining works well in fluid samples too, which matters because mesothelioma often presents with a pleural effusion before a tissue biopsy is available. Studies on effusion cytology specimens found that combining BAP1 immunohistochemistry with a separate test for p16 deletion improved sensitivity, catching more true cases of malignancy while maintaining high specificity.¹⁰ BAP1 staining also has a practical edge when the sample is small, because it can be interpreted even when only a few cells are available.¹¹ A separate study pairing BAP1, MTAP, and EZH2 staining with p16 deletion testing found each marker had 100 percent specificity on its own, with varying sensitivity, reinforcing the value of a panel approach.¹²

BAP1 and Mesothelioma Subtypes

Mesothelioma comes in three main histological subtypes: epithelioid (the most common and generally least aggressive), sarcomatoid (rarer and more aggressive), and biphasic (a mixture of both). BAP1 loss is not evenly distributed among them. One study found that 77 percent of epithelioid cases had lost BAP1, while none of the sarcomatoid cases showed loss. About half of biphasic tumors lacked BAP1.¹³ This pattern makes biological sense: sarcomatoid mesotheliomas appear to be driven by a different set of genetic events, and BAP1 loss is strongly tied to the epithelioid end of the spectrum. A large-scale analysis confirmed that BAP1 staining patterns correlate with histological subtype, molecular clustering, and markers of epithelial-to-mesenchymal transition.¹⁴

This is clinically relevant because it means BAP1 staining is most useful as a diagnostic and prognostic tool in the epithelioid and biphasic categories. In a sarcomatoid tumor, a retained BAP1 stain does not mean the tumor is benign; it just means that particular gene is not the main driver. Pathologists and oncologists factor this in when choosing which molecular tests to order.

Survival and the Germline BAP1 Paradox

Here is where the BAP1 story gets counterintuitive. You might expect that a gene mutation making someone more susceptible to cancer would also mean a worse prognosis. For germline BAP1 mutations, the opposite appears to be true. A study comparing mesothelioma patients with inherited BAP1 mutations to a large national cancer registry cohort found that germline carriers survived about seven times longer. Their median survival was five years, compared with under one year for the registry population. Five-year survival was 47 percent for carriers versus about 7 percent for the registry group.¹⁵ Within the germline carrier group, patients with peritoneal mesothelioma or those who developed a second malignancy alongside mesothelioma tended to do even better, with a median survival of about ten years.

Several factors likely contribute to this survival advantage. Germline BAP1-mutant mesotheliomas are overwhelmingly epithelioid, the subtype that responds best to treatment and grows more slowly. The tumors also tend to have a more inflamed microenvironment (discussed below), which may help the immune system keep the cancer in check. And because germline carriers are often identified through family histories and surveillance programs, their cancers may be caught earlier. Still, the survival difference is dramatic enough that it does not reduce to lead-time bias alone, and the improved prognosis has been observed independently of sex and age.

BAP1 Loss and the Immune Microenvironment

One of the most active areas of BAP1 research involves its effect on the tumor’s immune landscape. When BAP1 is lost, the tumor appears to become more “inflamed,” meaning immune cells infiltrate the tumor more densely and immune checkpoint molecules are upregulated. Research on tissue samples has shown that BAP1-low tumors are enriched for a specific population of CD8-positive T cells in a state called precursor exhaustion, and that these tumors express higher levels of the checkpoint receptors PD-L1, PD-1, and LAG3.¹⁶ Precursor-exhausted T cells are thought to be the population most capable of being “reawakened” by checkpoint-blocking immunotherapy drugs, which makes BAP1 loss a logical candidate biomarker for predicting who will respond to these treatments.

Data from mouse models of mesothelioma supports this idea: tumors with low Bap1 expression responded better to immune checkpoint inhibitors, with responders showing significantly lower Bap1 levels than non-responders. Similar patterns have been observed in melanoma, renal cancer, and lung cancer patients, where low BAP1 expression also tracks with better immunotherapy outcomes.¹⁶ An independent analysis in peritoneal mesothelioma reached a concordant conclusion: BAP1 loss correlates with an inflammatory tumor microenvironment and could help identify patients most likely to benefit from checkpoint inhibitor therapy.¹⁷ This is still being validated prospectively, but it fits with the broader observation that BAP1-deficient mesotheliomas behave differently from their BAP1-intact counterparts.

Targeted Therapies Under Investigation

Because BAP1 loss impairs DNA repair, an obvious therapeutic strategy is to pile on additional DNA repair stress using drugs called PARP inhibitors. The logic, known as synthetic lethality, is that a cell already crippled in one repair pathway may be unable to survive if a second pathway is also blocked. The early clinical results have been mixed. A phase 2 trial of rucaparib in BAP1-deficient or BRCA1-deficient mesothelioma met its prespecified criteria for success, achieving a disease control rate of 58 percent at 12 weeks and 23 percent at 24 weeks, with manageable side effects.¹⁸

However, a separate phase 2 trial of the PARP inhibitor olaparib found that BAP1 status did not predict sensitivity. In fact, patients with germline BAP1 mutations appeared to have worse outcomes on olaparib, contrary to the initial hypothesis. Preclinical experiments confirmed this, showing that BAP1 loss induced by gene editing did not make mesothelioma cell lines more sensitive to PARP inhibitors.¹⁹ A trial of another PARP inhibitor, niraparib, in BAP1-deficient and other DNA damage response-deficient tumors is exploring whether specific subsets of patients respond differently.²⁰ Overall, the PARP inhibitor story in BAP1-mutant mesothelioma is unsettled, and the drugs cannot be recommended specifically on the basis of BAP1 status alone.

A more mechanistically targeted approach involves EZH2 inhibitors. When BAP1 is lost, an enzyme complex called PRC2 (of which EZH2 is the catalytic engine) becomes overactive, silencing tumor suppressor genes it normally would not touch. This creates a selective vulnerability: blocking EZH2 disproportionately harms BAP1-deficient cells while leaving normal cells relatively unscathed.²¹ A phase 2 trial of the EZH2 inhibitor tazemetostat in patients with BAP1-inactivated pleural mesothelioma showed a disease control rate of 54 percent at 12 weeks. Complete responses were not observed, and confirmed partial responses were rare, but the drug showed enough signal to continue investigation.²²

Preclinical work is already pushing beyond single-agent EZH2 inhibition. One laboratory study found that combining an EZH2 inhibitor with an ATM inhibitor (ATM being another DNA damage response protein) produced strong synergy specifically in BAP1-deficient mesothelioma cell lines. BAP1-proficient lines showed little to no effect from the same combination even at high drug doses.²³ Combinations like these, designed to exploit multiple vulnerabilities that arise specifically from BAP1 loss, represent the direction much of the field is heading.

Metabolic Rewiring in BAP1-Deficient Tumors

BAP1 loss does not just affect DNA repair and gene silencing. It also reshapes the metabolic profile of mesothelioma cells. BAP1 loss-of-function mutations have been identified as a major contributor to the metabolic rewiring seen in malignant pleural mesothelioma, altering how cells handle energy production and oxidative stress.²⁴ Research has also found that BAP1-altered mesothelioma depends on the mevalonate pathway, a chain of biochemical reactions best known as the pathway targeted by cholesterol-lowering statin drugs.²¹ Whether this dependency can be exploited therapeutically, perhaps by combining statins or mevalonate pathway inhibitors with other targeted drugs, remains an open question, but it highlights how deeply BAP1 loss rewires the tumor’s biology.

Structural Effects of Cancer-Linked BAP1 Mutations

Not all BAP1 mutations are created equal. The BAP1 gene is large, and cancer-associated mutations hit many different positions along it. Some of these mutations sit right in the enzyme’s active site and directly disable its ability to remove ubiquitin tags. But many cancer-linked mutations are found far from the active site, and understanding how those distant mutations cause trouble has been a puzzle. Structural studies have shown that several such mutations destabilize the protein and increase its tendency to aggregate. More subtly, some distant mutations cause allosteric destabilization, meaning they send ripples through the protein’s structure that disrupt regions far from the mutation itself.²⁵ This explains why so many different BAP1 mutations, scattered across the gene, can all lead to the same functional outcome: a protein that cannot do its job.

Genetic Testing and Surveillance for Families

When a mesothelioma patient is found to carry a germline BAP1 mutation, the implications extend far beyond that individual. Because the mutation follows an autosomal dominant pattern, each first-degree relative has a 50 percent chance of carrying the same variant. Clinical practice guidelines recommend that predictive genetic testing be offered to at-risk relatives, typically starting in the late teenage years, when surveillance for associated cancers may begin.⁶

A consensus monitoring strategy for confirmed carriers has been proposed that prioritizes early diagnosis while minimizing exposure to ionizing radiation. The multidisciplinary approach typically involves regular dermatological exams (for melanoma and characteristic skin lesions), ophthalmologic screening (for uveal melanoma), abdominal imaging (for renal cell carcinoma), and periodic chest imaging or clinical evaluation (for mesothelioma).²⁶ The challenge is that mesothelioma screening in particular lacks a proven early-detection tool comparable to, say, mammography for breast cancer. Low-dose CT scans can detect pleural changes, but there is no consensus on how often to image or when an abnormal finding warrants intervention.

One important wrinkle in family testing: standard practice is to test relatives for the specific BAP1 variant already identified in the family. But a case report described a family where two different BAP1 mutations were found in different branches, meaning testing for only the known family variant would have missed the second one. The authors argued for offering broad gene panel testing, especially in families where the known variant cannot fully account for all the cancers that have occurred.²⁷ This is an edge case, but it illustrates the evolving thinking around how thorough genetic workups for cancer predisposition should be.

Peritoneal Versus Pleural Mesothelioma

BAP1 alterations are prominent in both pleural mesothelioma (which arises in the lining of the lungs) and peritoneal mesothelioma (which arises in the abdominal lining), but the genetic landscape differs between them. In the large genomic analysis mentioned earlier, the five most commonly altered genes in pleural mesothelioma were CDKN2A, BAP1, CDKN2B, NF2, and MTAP; in peritoneal mesothelioma, BAP1 topped the list, followed by NF2, with CDKN2A and CDKN2B being significantly less common.⁴ This means peritoneal mesothelioma is even more BAP1-centric than its pleural counterpart, while pleural tumors tend to carry more co-occurring alterations in cell-cycle control genes. These differences may partly explain why peritoneal mesothelioma generally responds better to treatment and carries a more favorable prognosis, particularly in patients with inherited BAP1 mutations, where median survival reached about ten years in one cohort.¹⁵

Understanding these site-specific genomic differences matters as the field moves toward biomarker-driven treatment selection. A therapy that works in BAP1-deficient peritoneal mesothelioma, where BAP1 loss is often the dominant genetic event, may not perform the same way in pleural mesothelioma, where BAP1 loss frequently co-exists with CDKN2A deletion, NF2 loss, and other alterations that can modify drug sensitivity. Ongoing trials are increasingly stratifying patients not just by BAP1 status but by the broader mutational profile and anatomical site.

1
PubMed Central. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression
2
PubMed Central. BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK
3
PubMed Central. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
4
British Journal of Cancer. Genomic landscape of pleural and peritoneal mesothelioma tumours
5
PubMed Central. High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
6
European Journal of Human Genetics. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome
7
PubMed Central. The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad
8
PubMed. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
9
Modern Pathology. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
10
The American Journal of Surgical Pathology. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
11
PubMed. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions
12
PubMed. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia
13
PubMed. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma
14
PubMed Central. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma
15
PubMed Central. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
16
JTO Clinical and Research Reports. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
17
PubMed Central. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
18
The Lancet Respiratory Medicine. Rucaparib in relapsed, BAP1-deficient malignant mesothelioma (MiST1): an open-label, single-arm, phase 2a trial
19
PubMed Central. Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
20
PubMed Central. Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
21
Cell Reports Medicine. BAP1-deficient mesothelioma is dependent on the mevalonate pathway and sensitive to EZH2 inhibition
22
PubMed. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
23
British Journal of Cancer. Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma
24
PubMed Central. Metabolic rewiring and redox alterations in malignant pleural mesothelioma
25
PubMed Central. Impacts of Cancer-associated Mutations on the Structure-Activity Relationship of BAP1
26
PubMed. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy
27
PubMed Central. Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing